Mohammad Hussain, MD
Hematology · Springfield, ILNPI 1427242767
Payments from drug & device makers
What this record shows
This record is dominated by education: $257 of the $346 with a category attached, or 74.4%. 5 manufacturers reported payments, led by Astellas Pharma US Inc at 46.9% of the total. That places this record below the midpoint for hematology clinicians in IL, where the typical reported total is $2,003.
Across 6 payments — averaging $57.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$162
- Daiichi Sankyo Inc.$78
- Takeda Pharmaceuticals U.S.A., Inc.$68
- AstraZeneca$20
- Regeneron Healthcare Solutions, Inc.$17
Across 7 payments — averaging $17,413 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$79K
- Pfizer$26K
- Beone Medicines USA, Inc.$17K
- Bristol Myers Squibb$48
What the payments were for
- Food & beverage$8926%
- Education$25774%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $162 |
| Daiichi Sankyo Inc. | 1 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $68 |
| AstraZeneca | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
How this compares
$346 in reported general payments places this provider in the 30th percentile of 49 hematology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 15 | $205,513 |
| EliquisApixaban | 28 | $17,560 |
| Lidocaine | 17 | $3,413 |
| Fentanyl | 18 | $1,828 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $1,352 |
| Oxycodone Hcl | 75 | $962 |
| Morphine Sulfate ErMorphine Sulfate | 23 | $863 |
| Anastrozole | 58 | $658 |
| Morphine Sulfate | 11 | $605 |
| Gabapentin | 26 | $506 |
| Dexamethasone | 18 | $486 |
| Fluconazole | 14 | $468 |
| Letrozole | 43 | $409 |
| Prochlorperazine Maleate | 29 | $380 |
| Levofloxacin | 31 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $162 | $205,51315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 49 hematology providers in Illinois.
Other hematology in Springfield
- Yogesh JethavaPark Ridge$560K
- David GrinblattEvanston$196K
- Jayesh MehtaChicago$183K
- Stephanie TsaiMaywood$160K
- Celalettin UstunChicago$153K
- Kunal DesaiChicago$150K
- John QuigleyChicago$132K
- Parameswa VenugopalChicago$122K
- Nadia KhanChicago$66K
- Seema SinghalChicago$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.